Obesity & MASH

Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)

Obesity

37%
Status1
End of Phase 2 FDA Meeting November 2024
Pemvidutide
(ALT-801)

MASH

55%
Status1
IMPACT Phase 2b MASH trial top line data in Q2 2025